Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets
Exousia Pro (OTCPINK:MAJI) has filed a provisional patent (#63/877,517) for a novel method of loading Extracellular Vesicles (EVs), marking a significant strategic advancement in exosome-based therapies. The technology, to be utilized under the Exousia Health division, enhances the efficiency and stability of therapeutic agent delivery through exosomes.
The innovation targets three major markets with a combined value exceeding $2.7 trillion: the pharmaceutical market ($1.77 trillion), nutraceuticals market ($500 billion), and cosmetics market ($450 billion). The company is preparing to file trademarks for new products leveraging this technology, representing one of two patent-ready technologies currently in development.
Exousia Pro (OTCPINK:MAJI) ha depositato un brevetto provvisorio (n. 63/877.517) per un metodo innovativo di caricamento di vescicole extracellulari (EV), segnando un importante avanzamento strategico nelle terapie a base di esosomi. La tecnologia, che sarà impiegata dalla divisione Exousia Health, migliora l'efficienza e la stabilità nella somministrazione di agenti terapeutici tramite esosomi.
L'innovazione si rivolge a tre mercati principali il cui valore complessivo supera i $2,7 trilioni: il mercato farmaceutico (1,77 trilioni di dollari), il mercato nutraceutico (500 miliardi di dollari) e quello dei cosmetici (450 miliardi di dollari). L'azienda si sta preparando a depositare marchi per nuovi prodotti basati su questa tecnologia, che rappresenta una delle due tecnologie pronte per la brevettazione attualmente in sviluppo.
Exousia Pro (OTCPINK:MAJI) ha presentado una solicitud de patente provisional (n.º 63/877.517) para un método novedoso de carga de vesículas extracelulares (EV), marcando un avance estratégico significativo en terapias basadas en exosomas. La tecnología, que se utilizará en la división Exousia Health, aumenta la eficiencia y la estabilidad en la entrega de agentes terapéuticos mediante exosomas.
La innovación está dirigida a tres mercados principales con un valor combinado superior a $2.7 billones: el mercado farmacéutico ($1.77 billones), el de nutracéuticos ($500 mil millones) y el de cosméticos ($450 mil millones). La compañía se prepara para registrar marcas comerciales para nuevos productos que aprovechen esta tecnología, que es una de las dos tecnologías listas para patentar que actualmente están en desarrollo.
Exousia Pro (OTCPINK:MAJI)는 외엑소좀(세포외 소포, EV) 탑재를 위한 혁신적 방법에 대해 임시 특허(번호 63/877,517)를 출원했으며, 이는 엑소좀 기반 치료법에서 중요한 전략적 진전입니다. 이 기술은 Exousia Health 부문에서 활용될 예정이며, 엑소좀이 전달하는 치료제의 효율성과 안정성을 향상시킵니다.
이 혁신은 총 가치가 $2.7조를 넘는 세 가지 주요 시장을 겨냥합니다: 제약 시장($1.77조), 뉴트라슈티컬 시장($5000억), 화장품 시장($4500억). 회사는 이 기술을 활용한 신제품의 상표 출원을 준비 중이며, 이는 현재 개발 중인 특허 준비 완료 기술 두 가지 중 하나입니다.
Exousia Pro (OTCPINK:MAJI) a déposé un brevet provisoire (n° 63/877,517) pour une méthode nouvelle de chargement des vésicules extracellulaires (EV), marquant une avancée stratégique majeure dans les thérapies à base d'exosomes. La technologie, qui sera utilisée au sein de la division Exousia Health, améliore l'efficacité et la stabilité de la délivrance d'agents thérapeutiques via les exosomes.
L'innovation vise trois marchés principaux dont la valeur combinée dépasse 2,7 000 milliards $ : le marché pharmaceutique (1 770 milliards $), le marché des nutraceutiques (500 milliards $) et le marché des cosmétiques (450 milliards $). La société se prépare à déposer des marques pour de nouveaux produits exploitant cette technologie, qui représente l'une des deux technologies prêtes à être brevetées actuellement en développement.
Exousia Pro (OTCPINK:MAJI) hat eine vorläufige Patentanmeldung (Nr. 63/877.517) für ein neuartiges Verfahren zur Beladung von extrazellulären Vesikeln (EV) eingereicht und damit einen bedeutenden strategischen Fortschritt für exosombasierte Therapien erzielt. Die Technologie, die unter der Exousia Health Division eingesetzt werden soll, verbessert Effizienz und Stabilität der Wirkstoffabgabe über Exosomen.
Die Innovation zielt auf drei Hauptmärkte mit einem kombinierten Wert von über $2,7 Billionen ab: den Pharmamarkt ($1,77 Billionen), den Nutraceuticals-Markt ($500 Milliarden) und den Kosmetikmarkt ($450 Milliarden). Das Unternehmen bereitet Markenanmeldungen für neue Produkte vor, die diese Technologie nutzen, und es handelt sich um eine von zwei derzeit entwickelten, patentbereiten Technologien.
- Filed strategic provisional patent for novel EV loading method
- Technology targets three massive markets worth over $2.7 trillion combined
- Company has second patent-ready technology in development
- Preparing to file trademarks for new products utilizing the technology
- Patent is still in provisional stage, not yet fully secured
- Products utilizing the technology are not yet market-ready
ORLANDO, FL / ACCESS Newswire / September 10, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company and innovator in exosome-based therapies, today announced a key strategic milestone towards expanding its commercial footprint and building significant shareholder value. The company has filed a new Provisional Patent (#63/877,517) that embodies a groundbreaking method for loading Extracellular Vesicles (EVs). This technological innovation is poised to give the company a significant competitive advantage.
The new provisional patent, which will be utilized under the company's Exousia Health division, covers a novel process for encapsulating active compounds into tiny, naturally-secreted vesicles known as exosomes. This method is designed to enhance loading efficiency and improve the stability and delivery of therapeutic agents. This technology has wide-ranging applications across three enormous markets:
Pharmaceuticals: The global pharmaceutical market is a multi-trillion dollar industry, with an estimated size of
$1.77 trillion in 2025.Nutraceuticals: The global nutraceuticals market is valued at over
$500 billion in 2025.Cosmetics: The global cosmetics market is also a multi-billion dollar industry, valued at over
$450 billion in 2025.
"The filing of this provisional patent marks a pivotal moment for Exousia Pro, as it represents one of two new patent-ready technologies we have in development," said Matt Dwyer, President of Exousia Pro, Inc. "This proprietary technology is a critical asset that will provide us with a powerful market edge. It will enable us to develop and introduce new, innovative products with enhanced efficacy for our growing patient base within Exousia Health, and beyond. We are actively preparing to file for trademarks on several new products that will leverage this loading method, further expanding our revenue opportunities and bringing tangible value to our shareholders."
About Us
Exousia Pro (formerly Marijuana, Inc.) is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology.The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Exousia Pro, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Exousia Pro, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the new provisional patent filed by Exousia Pro (MAJI)?
What markets will Exousia Pro's new EV loading technology target?
How many patent-ready technologies does Exousia Pro currently have in development?
What is the potential impact of the new patent on Exousia Pro's business?
What are the next steps for Exousia Pro following the provisional patent filing?
